Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27432666 | 0.81 | CYP11B2 (0.42) | CYP11B2CYP11B1PDE3BPDE3AIDH1 | |
| SCHEMBL30954127 | 0.81 | CYP11B2 (0.42) | CYP11B2CYP11B1PDE3BPDE3AIDH1 | |
| SCHEMBL27432572 | 0.81 | CYP11B2 (0.42) | CYP11B2CYP11B1PDE3BPDE3AIDH1 | |
| SCHEMBL3347754 | 0.79 | PDE3B (0.44) | CYP11B2CYP11B1PDE3BPDE3APTGER3 | |
| SCHEMBL30954096 | 0.79 | CYP11B2 (0.40) | CYP11B2CYP11B1PDE3BPDE3AIDH1 | |
| SCHEMBL27433176 | 0.79 | CYP11B2 (0.40) | CYP11B2CYP11B1PDE3BPDE3AIDH1 | |
| SCHEMBL27432475 | 0.79 | HTR1A (0.45) | CYP11B2CYP11B1PDE3BPDE3AIDH1 | |
| SCHEMBL1744601 | 0.78 | PDE3B (0.43) | CYP11B2CYP11B1PDE3BPDE3AIDH1 | |
| SCHEMBL8600208 | 0.78 | CYP11B2 (0.42) | CYP11B2CYP11B1PDE3BPDE3APTGER3 | |
| SCHEMBL1744896 | 0.77 | CYP11B2 (0.41) | CYP11B2CYP11B1PDE3BPDE3AIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180289718-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-10-11 | — | — | US | disclosed |
| US-10016439-B2 | Fused imidazole compounds | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-3099672-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO Pharmaceutical Co., Ltd. (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| WO-2015115673-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289718-A1 | FUSED IMIDAZOLE COMPOUNDS | GABRA5, CHRNA5, GABRP | CYP11B2 209/4885CYP11B1 150/4885PDE3B 122/4885 |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | GABRA5, CHRNA5, GABRP | CYP11B2 209/4885CYP11B1 150/4885PDE3B 122/4885 |
| US-10016439-B2 | Fused imidazole compounds | GABRA5, CHRNA5, GABRP | CYP11B2 209/4885CYP11B1 150/4885PDE3B 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.